Anavex Life Sciences (AVXL) to Release Quarterly Earnings on Wednesday

Posted by Defense World Staff on Feb 4th, 2025

Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.

Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) last posted its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03.

Anavex Life Sciences Stock Performance

Shares of AVXL opened at $8.64 on Tuesday. The company has a 50 day moving average price of $9.98 and a 200-day moving average price of $7.59. Anavex Life Sciences has a fifty-two week low of $3.25 and a fifty-two week high of $14.44. The stock has a market capitalization of $732.84 million, a PE ratio of -16.62 and a beta of 0.69.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on AVXL shares. D. Boral Capital reiterated a “buy” rating and issued a $46.00 price target on shares of Anavex Life Sciences in a report on Tuesday, January 28th. HC Wainwright reissued a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a research report on Tuesday, January 28th.

Check Out Our Latest Analysis on AVXL

Anavex Life Sciences Company Profile

(Get Free Report)

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.